Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan

Sugimoto, Katsutoshi; Moriyasu, Fuminori; Kobayashi, Yohnosuke; Saito, Kazuhiro; Takeuchi, Hirohito; Ogawa, Satoshi; Ando, Mayumi; Sano, Tsuyoshi; Mori, Toshifumi; Furuichi, Yoshihiro; Nakamura, Ikuo

doi:10.1007/s11604-015-0442-1

Cited by 44 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The participants were classified into the hepatitis B virus-positive and hepatitis B-negative groups, and an increase in T.BIL by >3 times [74 µmol/l following IRE vs. 23 µmol/l prior to IRE (3.2 times greater)] and a similar increase in D.BIL [45 µmol/l after IRE vs. 12 µmol/l prior to IRE (3.8 times greater)] were only observed in the hepatitis B-positive group at 3-5 days following treatment. The increase in AST and ALT levels observed in the present study was consistent with previous studies; however the range of increase varied between studies (18,(29)(30)(31). The minimal increase that was observed in the present study may be explained by the time points of the measurements.…”

Section: Discussionsupporting

confidence: 92%

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

et al. 2018

View full text Add to dashboard Cite

Liver cancer is often associated with chronic liver diseases. Treatment with percutaneous irreversible electroporation (IRE) may preserve liver function. In the present study, the clinical data of 29 patients with liver tumors between July 2015 and December 2016, all of whom underwent liver IRE at Fuda Cancer Hospital, Guangzhou, China was retrospectively reviewed. All the patients survived the treatment. Of the 29 patients, 7 were positive for hepatitis B, 15 had hepatocellular carcinoma (HCC) and 7 had pancreatic cancer with liver metastases. All patients survived IRE. Despite liver-protective treatment prior to IRE, the mean alanine transaminase (ALT) and aspartate transaminase (AST) levels were significantly elevated 1-2 days after IRE, to 540 and 712 U/l, respectively; however they had returned to the preoperative values by 2 weeks following IRE. Prior to IRE, the mean total bilirubin and direct bilirubin measurement levels were normal; however, 8-10 days after IRE, they had increased to 24 U/l and 12 µmol/l, respectively, and had returned back to the preoperative levels by 2 weeks after IRE. This first group included all patients. The result of the 4 subgroups of cancer patients demonstrated a variation between different measurement days and recovery with patients positive for the hepatitis B virus taking the longest duration to recover (17±3 days) meanwhile patients with pancreatic cancer with liver metastases took the shortest time to achieve recovery (10.78±2 days). The findings of the present study indicate that hepatic injury caused by IRE is transient and self-limiting in patients with liver tumors.

show abstract

Section: Discussionsupporting

confidence: 92%

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In 2015, Sugimoto and Kobayashi [50] conducted a prospective clinical trial to assess the safety of IRE in Japan including 5 patients with 6 HCCs enrolled. Within the study, 5 of the 6 tumors were successfully treated and no local recurrence at 244 ± 55 days of follow-up.…”

Section: Ire Of Hepatic Tumors In Clinical Settingsmentioning

confidence: 99%

Irreversible electroporation in primary and metastatic hepatic malignancies

Lyu

Wang

et al. 2017

Medicine

View full text Add to dashboard Cite

Background:Liver cancer makes up a huge percentage of cancer mortality worldwide. Irreversible electroporation (IRE) is a relatively new minimally invasive nonthermal ablation technique for tumors that applies short pulses of high frequency electrical energy to irreversibly destabilize cell membrane to induce tumor cell apoptosis.Methods:This review aims to investigate the studies regarding the use of IRE treatment in liver tumors and metastases to liver. We searched PubMed for all of IRE relevant English language articles published up to September 2016. They included clinical trials, experimental studies, observational studies, and reviews. This review manuscript is nothing with ethics issues and ethical approval is not provided.Results:In recent years, increasingly more studies in both preclinical and clinical settings have been conducted to examine the safety and efficacy of this new technique, shedding light on the crucial advantages and disadvantages that IRE possesses. Unlike the current leading thermal ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, IRE requires shorter ablation time without damaging adjacent important vital structures.Conclusion:Although IRE has successfully claimed its valuable status in the field of hepatic cancer treatment both preclinical and clinical settings. In order to systemically test and establish its safety and efficacy for clinical applications, more studies still need to be conducted.

show abstract

“…In a small series from Japan, Sugimoto et al35 described their results of treating 5 patients with 6 HCC lesions with IRE. Tumors ranged in size from 1.1 cm to 2.8 cm.…”

Section: Ire For Hccmentioning

confidence: 99%

“…Several authors have noted the increased technical precision required to ablate tumors using IRE compared to RFA 22,35. RFA requires the placement of one large catheter within the center of the lesion to be ablated, whereas IRE requires the placement of multiple (2–5) probes, all in parallel and bracketed around the tumor to incorporate the lesion in the electrical field.…”

Section: Challenges For Ire In the Treatment Of Hccmentioning

confidence: 99%

Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

Zimmerman¹,

Grand

Charpentier³

2017

JHC

View full text Add to dashboard Cite

Irreversible electroporation (IRE) is a novel form of tissue ablation that uses high-current electrical pulses to induce pore formation of the cell lipid bilayer, leading to cell death. The safety of IRE for ablation of hepatocellular carcinoma (HCC) has been established. Outcome data for ablation of HCC by IRE are limited, but early results are encouraging and suggest equivalency to the outcomes obtained for thermal ablation for appropriately selected, small (<3 cm) tumors. Long-term oncologic efficacy and histopathologic response data have not been published, and therefore, application of IRE for the treatment of HCC should still be viewed with caution.

show abstract

Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan

Abstract: The results of this study suggest that image-guided percutaneous IRE can achieve satisfactory local disease control, particularly for small HCCs, and is well tolerated by patients.

Cited by 44 publications

References 22 publications

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

Irreversible electroporation in primary and metastatic hepatic malignancies

Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

Contact Info

Product

Resources

About